An antibody-toxin conjugate directed against a human mammary cancer antigen.

Abstract

A conjugate has been constructed consisting of diphtheria toxin fragment A (DTA) linked to a monoclonal antibody, BLMRL-HMFG-Mc5 (MC5), directed against a mammary cancer antigen. The conjugate retains both binding and DTA enzymatic activity when tested against target MCF-7 cells, although the conjugate binds less well than the unconjugated antibody. The conjugate is toxic to MCF-7 cells. Toxicity is both dose- and time-dependent. Half-maximal toxicity is observed with 2-5 X 10(-8) M conjugate after 5 days of incubation. However, the conjugate need only be in contact with the cells for 1 day in order to effect complete killing by 5 days. The earliest that an effect can be seen on cell growth is 2 days. When tested against WRK-1 rat mammary tumor cells, the conjugate is inactive.

• Authors: M E Monaco, J Mack, M D Dugan, R Ceriani
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 464 Pg. 389-99 ( 1986) ISSN: 0077-8923 [Print] United States
• PMID: 3460375 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antibodies
• Antigens, Neoplasm
• Ricin

Topics

• Antibodies
• Antibody Specificity
• Antigens, Neoplasm (immunology)
• Breast Neoplasms (immunology)
• Cell Line
• Cell Survival (drug effects)
• Chromatography, Gel
• Dose-Response Relationship, Drug
• Female
• Humans
• Ricin
• Time Factors